Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review.
Charan Yerasi, Brian C Case, Brian J Forrestal...
https://pubmed.ncbi.nlm.nih.gov/32138967/Actively Recruiting
Led by Fundación EPIC · Updated on 2026-09-30
94
Participants Needed
9
Research Sites
52 weeks
Total Duration
Researchers are evaluating vasomotor function in patients with coronary artery disease by comparing two devices used in large blood vessels of 3.5 mm or greater. The study is randomized, controlled, open, and conducted at multiple centers, focusing on the effects observed 8 months after treatment with either a drug-coated balloon DCB or a drug-eluting stent DES. The goal is to analyze differences in vessel response and morphology after these interventions. Participants receive either the drug-coated balloon or the drug-eluting stent as part of their percutaneous coronary intervention PCI procedure. The study compares vascular function and structure between these two groups, including angiographic restenosis, luminal diameter and area assessed by optical coherence tomography, strut coverage in the DES group, and vascular architecture in the DCB group. These assessments take place 8 months post-treatment. Throughout the study, participants undergo detailed imaging and functional testing to measure vessel responses, including infusion of acetylcholine and nitroglycerin. Researchers evaluate the percentage of vessels showing a positive response, changes in luminal diameter, and vessel structure using optical coherence tomography. Safety is monitored by excluding participants with contraindications or significant health issues. The study continues through primary outcome assessment at 8 months and concludes by December 2027.
CONDITIONS
DRUG RELEASING BALL vs. PHARMACOACTIVE STENT IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY) IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY)
I
IÑIGO LOZANO MARTINEZ-LUENGAS, MD, PhD
F
FUNDACION EPIC
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fundación EPIC
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single treatment at enrollment
Participants receive either the drug-coated balloon or the drug-eluting stent as part of their percutaneous coronary intervention procedure.
1 procedure visit
Duration - 8 months
Participants undergo imaging and functional tests to assess vessel response and structure 8 months after treatment.
Scheduled follow-up visits for assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Charan Yerasi, Brian C Case, Brian J Forrestal...
https://pubmed.ncbi.nlm.nih.gov/32138967/Josep Gomez-Lara, Loreto Oyarzabal, Luis Ortega-Paz...
https://pubmed.ncbi.nlm.nih.gov/34729992/Salvatore Brugaletta, Jung Ho Heo, Hector M Garcia-Garcia...
https://pubmed.ncbi.nlm.nih.gov/22507972/Takamitsu Nakamura, Brigitta C Brott, Irena Brants...
https://pubmed.ncbi.nlm.nih.gov/21349465/Fundación EPIC
Lead Sponsor